342 related articles for article (PubMed ID: 24563540)
1. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Musi E; Ambrosini G; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
[TBL] [Abstract][Full Text] [Related]
3. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
[TBL] [Abstract][Full Text] [Related]
4. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
[TBL] [Abstract][Full Text] [Related]
5. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
[TBL] [Abstract][Full Text] [Related]
6. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death.
Ambrosini G; Musi E; Ho AL; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2013 May; 12(5):768-76. PubMed ID: 23443802
[TBL] [Abstract][Full Text] [Related]
8. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.
Cerne JZ; Hartig SM; Hamilton MP; Chew SA; Mitsiades N; Poulaki V; McGuire SE
Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2130-9. PubMed ID: 24595385
[TBL] [Abstract][Full Text] [Related]
10. Chloroquine Sensitizes
Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
[TBL] [Abstract][Full Text] [Related]
11. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.
Chen X; Wu Q; Depeille P; Chen P; Thornton S; Kalirai H; Coupland SE; Roose JP; Bastian BC
Cancer Cell; 2017 May; 31(5):685-696.e6. PubMed ID: 28486107
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.
Park JJ; Stewart A; Irvine M; Pedersen B; Ming Z; Carlino MS; Diefenbach RJ; Rizos H
Cancer Gene Ther; 2022 Oct; 29(10):1384-1393. PubMed ID: 35352024
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH
Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078
[TBL] [Abstract][Full Text] [Related]
14. Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071.
Piperno-Neumann S; Larkin J; Carvajal RD; Luke JJ; Schwartz GK; Hodi FS; Sablin MP; Shoushtari AN; Szpakowski S; Chowdhury NR; Brannon AR; Ramkumar T; de Koning L; Derti A; Emery C; Yerramilli-Rao P; Kapiteijn E
Mol Cancer Ther; 2020 Apr; 19(4):1031-1039. PubMed ID: 32029634
[TBL] [Abstract][Full Text] [Related]
15. Genetic and clinico-pathologic analysis of metastatic uveal melanoma.
Griewank KG; van de Nes J; Schilling B; Moll I; Sucker A; Kakavand H; Haydu LE; Asher M; Zimmer L; Hillen U; Thompson JF; Scolyer RA; Schadendorf D; Murali R
Mod Pathol; 2014 Feb; 27(2):175-83. PubMed ID: 23887304
[TBL] [Abstract][Full Text] [Related]
16. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
Ambrosini G; Sawle AD; Musi E; Schwartz GK
Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
[TBL] [Abstract][Full Text] [Related]
17. Mutations in GNA11 in uveal melanoma.
Van Raamsdonk CD; Griewank KG; Crosby MB; Garrido MC; Vemula S; Wiesner T; Obenauf AC; Wackernagel W; Green G; Bouvier N; Sozen MM; Baimukanova G; Roy R; Heguy A; Dolgalev I; Khanin R; Busam K; Speicher MR; O'Brien J; Bastian BC
N Engl J Med; 2010 Dec; 363(23):2191-9. PubMed ID: 21083380
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
[TBL] [Abstract][Full Text] [Related]
19. GNAQ and GNA11 mutations in uveal melanoma.
Shoushtari AN; Carvajal RD
Melanoma Res; 2014 Dec; 24(6):525-34. PubMed ID: 25304237
[TBL] [Abstract][Full Text] [Related]
20. Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas.
Schneider B; Riedel K; Zhivov A; Huehns M; Zettl H; Guthoff RF; Jünemann A; Erbersdobler A; Zimpfer A
Pathol Oncol Res; 2019 Oct; 25(4):1319-1325. PubMed ID: 29209985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
